QCG
VNDA icon

Quadrant Capital Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Quadrant Capital Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-160
Closed -$676 – 2776
2023
Q4 		$676 Buy
160
+43
+37% +$173 ﹤0.01% 2593
2023
Q3 		$506 Sell
117
-4,874
-98% -$27.1K ﹤0.01% 2567
2023
Q2 		$32.9K Buy
4,991
+4,612
+1,217% +$29.6K ﹤0.01% 1464
2023
Q1 		$2.57K Sell
379
-134
-26% -$942 ﹤0.01% 2381
2022
Q4 		$3.79K Sell
513
-1,356
-73% -$13.2K ﹤0.01% 2271
2022
Q3 		$18K Buy
1,869
+1,853
+11,581% +$19.6K ﹤0.01% 1619
2022
Q2 		$0 Hold
16
– – ﹤0.01% 2752
2022
Q1 		$0 Hold
16
– – ﹤0.01% 2708
2021
Q4 		$0 Sell
16
-32
-67% -$558 ﹤0.01% 2709
2021
Q3 		$1K Buy
48
+8
+20% +$140 ﹤0.01% 2404
2021
Q2 		$1K Buy
40
+24
+150% +$429 ﹤0.01% 2339
2021
Q1 		$0 Hold
16
– – ﹤0.01% 2464
2020
Q4 		$0 Buy
+16
New +$193 ﹤0.01% 2380
2020
Q3 		– Sell
-45
Closed -$1K – 2317
2020
Q2 		$1K Buy
+45
New +$509 ﹤0.01% 2149

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrant Capital Group's VNDA Position: Q1 2024 in Review

Quadrant Capital Group sold out of Vanda Pharmaceuticals (VNDA) in Q1 2024, closing a stake of 160 shares — an estimated $676 sold.

Quadrant Capital Group first reported a position in VNDA in Q2 2020 and held it in 14 quarters. The position peaked at $32.9K in Q2 2023. 144 funds tracked by Wall St. Rank hold VNDA as of Q1 2024.

  • Quadrant Capital Group reported no remaining Vanda Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 160 Vanda Pharmaceuticals shares in Q1 2024, an estimated $676.
  • Quadrant Capital Group first reported a position in Vanda Pharmaceuticals in Q2 2020 and held it in 14 quarters.
  • Quadrant Capital Group's Vanda Pharmaceuticals position peaked at $32.9K in Q2 2023.
  • 144 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2024.

Based on Quadrant Capital Group's 13F filing for Q1 2024, filed 15 May 2024.